Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547297 · ClinicalTrials.gov registry record
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
A clinical trial, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- 212
- Enrollment target
NCT03547297: Clinical Trial study, sponsored by Alnylam Pharmaceuticals.
NCT03547297 is a clinical trial that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 212 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03547297 was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- 212 participants
- Enrollment target
Study Summary
This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2019-01-15 |
Why NCT03547297 stopped before completion
NCT03547297 is an observational study that tracks outcomes without assigning an intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03547297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03547297 about?
NCT03547297 is a clinical study titled "INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP". This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
What is the current status of trial NCT03547297?
This trial is currently terminated. The enrollment target is 212 participants. The study started on 2018-05-29. Estimated completion is 2019-01-15.
Who is sponsoring clinical trial NCT03547297?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI